We induced brain edema in 72 rats by injecting 5 fil of 3.0% wt vol polyvinyl acetate into the left internal carotid artery, producing permanent embolization in the left cerebral hemisphere, which developed ipsilateral brain edema reproducibly. Edema was assessed 24 hours after embolization by determining the brain water content and the sodium and potassium concentrations. In this model, the free radical scavenger MCI-186 at 1.0 and 3.0 mg/kg i.v. prevented brain edema in a dose-dependent manner. At 3.0 mg/kg i.v., MCI-186 significantly reduced water content by 1.5% and improved the sodium-potassium balance to within the normal range in the embolized left hemisphere. Dexamethasone at 1.0 mg/kg i.v. did but at 3.0 mg/kg i.v. did not significantly inhibit the development of brain edema. Indomethacin at 4.0 mg/kg i.p. had no effect on brain edema. We suggest that the cyclooxygenase metabolites of arachidonic acid liberated from neuronal cell membrane phospholipids are not likely to be involved in the pathogenesis of permanent brain edema induced by polyvinyl acetate. Our results suggest that MCI-186 attenuates brain edema by suppressing the production of lipoxygenase metabolites, including free radicals or lipid peroxides, and that it may prove valuable for the treatment of brain edema associated with cerebral ischemia. (Stroke 1989;20:1236-1240) A lthough brain edema is a serious clinical complication in acute cerebrovascular disorders, there are few drugs available for therapeutic intervention. For this reason, many attempts have been made to develop new agents for the therapy of brain edema. However, experimental brain edema induced by permanent and transient ischemia responds differently to drugs. For example, indomethacin effectively reduces the formation of edema in animals subjected to transient ischemia but has no such action in prolonged cerebral ischemia.
A lthough brain edema is a serious clinical complication in acute cerebrovascular disorders, there are few drugs available for therapeutic intervention. For this reason, many attempts have been made to develop new agents for the therapy of brain edema. However, experimental brain edema induced by permanent and transient ischemia responds differently to drugs. For example, indomethacin effectively reduces the formation of edema in animals subjected to transient ischemia but has no such action in prolonged cerebral ischemia. 1 Thus, the choice of an appropriate experimental model is crucial in the evaluation of new drugs to counteract brain edema. A major remaining difficulty is that the biochemical mechanisms underlying brain edema formation are poorly understood. Among the existing hypotheses are that changes in membrane phospholipids and in arachidonic acid metabolites play an important role in the pathogenesis of brain edema. MCI-186, a novel free radical scavenger, 4 has a strong antiedema activity in rats subjected to transient cerebral ischemia. 5 Moreover, MCI-186 inhibits both nonenzymatic lipid peroxidation 4 and lipoxy-genase activity 6 in vitro. In consideration of these factors the antiedema activity of MCI-186 has been evaluated compared with indomethacin and dexamethasone in a model of permanent brain infarction induced by polyvinyl acetate (PVA) 7 in rats. We sought to substantiate the hypothesis that the cyclooxygenase metabolites of arachidonic acid are unlikely to be involved in the development of brain edema.
Materials and Methods
We used 72 male Wistar rats weighing 280-310 g housed four to a cage 17.5x30.0x34.5 cm equipped with wood shavings for bedding. Food and water were provided ad libitum. The temperature in the animal rooms was maintained at 23 ±1° C, and the light:dark schedule was 12^12 hours (light on at 7:00 AM).
The rats were anesthetized with ether during surgery. Body temperature was kept close to 37° C with a water-circulating heating pad during and after surgery until recovery from the anesthesia. The left internal and external carotid and pterygopalatine arteries were exposed at the anterior cervical level. A polyethylene tube (PE-20, Clay Adams) for the injection of emboli was filled with 3 /A saline and inserted antidromically through the left external carotid artery; the tip of the tube was fixed below the bifurcation at the level of the carotid body. For embolization, 5 fi\ of 3.0% wt:vol PVA (Wako Pure Chemicals) in a solution of ethanol (50% by volume) was injected into the left common carotid artery through the PE-20 tube for 10 seconds. This enabled us to inject PVA as emboli without interrupting the flow of blood through the left common carotid artery into the internal carotid artery. During the injection of PVA, the flow of blood through the pterygopalatine artery was stopped temporarily with a clip; 30 seconds after PVA embolization, this clip was removed from the artery. Immediately after removal of the PE-20 tube, the external carotid artery was ligated both above and below the punctured site and the wound was closed. The operated rats then were allowed free movement in their cages until sampling. (This study was completed in November 1985 before an Institutional Animal Care Committee was established; however, we performed the study carefully, not deviating from the draft guidelines of the Institutional Animal Care Committee.)
The clinical status of each rat 24 hours after PVA embolization was scored as 0, normal; 1, paralysis of a contralateral hind limb; 2, paralysis of contralateral fore and hind limbs; 3, loss of righting reflex, and 4, death.
Rats were studied in groups of eight, and each rat was decapitated 24 hours after the neurologic symptoms were scored. After removal of the brain, the cerebellum was discarded. The water content of both hemispheres was determined as the percent difference in tissue weight before and after drying for 3 days at 100° C. Sodium and potassium concentrations as milliequivalents per kilogram dry weight were determined in both desiccated hemispheres using flame photometry.
The drugs used were MCI-186 (3-methyll-phenyl-2-pyrazolin-5-one; Mitsubishi Kasei Corp., Yokohama, Japan), dexamethasone (Dexascheroson in injectable form; Nihon Schering KK), and indomethacin (Nihon Merck). MCI-186 was freshly dissolved in 1.0N NaOH, the pH being adjusted to 8.5 with 1.0N HC1. Dexamethasone was diluted with saline for intravenous injection. Indomethacin was suspended in 1% tragacanth gum for intraperitoneal administration. The injection volumes were 1.0 ml/kg for the intravenous route and 5 ml/kg for intraperitoneal delivery. MCI-186 at 1.0 and 3.0 mg/kg and dexamethasone at 1.0 and 3.0 mg/kg were injected 5 minutes and indomethacin at 4.0 mg/kg 30 minutes before PVA embolization. Four control groups with PVA embolization received vehicle alone at the injection volumes above; three control groups received saline. The rats were randomized to treatment in a single-blind manner.
All data are expressed as mean±SEM; nonscoring data were also analyzed. Neurologic scores of the control and corresponding drug-treated groups were compared using the Kruskal-Wallis method followed by Dunn's test. The remaining data were compared using multigroup repeated-measures analysis of variance followed by Dunn's test;p<0.05 was chosen to indicate significance. Results Twenty-four hours after PVA embolization, all control rats exhibited abnormal behavior, with neurologic scores of >1. In the control group, one rat died <24 hours after PVA embolization, and the mean neurologic score of the group was 2.1. The mean neurologic score of the animals receiving 1.0 mg/kg MCI-186 was 1.4. MCI-186 at 3.0 mg/kg significantly reduced the mean neurologic score to 0.8 ( Figure 1 ). Both doses of dexamethasone had only a slight effect on neurologic score compared with the corresponding control group. Indomethacin did not influence the neurologic score ( Table 1) .
As shown in Table 1 and Figure 2 , in each control group PVA embolization produced lateralized edema of the left cerebral hemisphere 24 hours later. Among the four control groups, water content varied from 81.9±0.4% to 82.4±0.3% in the embolized left hemispheres and from 80.2±0.1% to 80.5±0.1% in the contralateral right hemispheres. The water content of the left hemispheres was always significantly different from that of the corresponding right hemispheres. Accompanying these changes in water content, the sodium concentration was increased significantly by 28.5-44.8% compared with that in the right hemispheres (Table 1, Figure 3 ). By contrast, the potassium concentration decreased by 4.0-12.9% compared with that in the right hemispheres (Table 1, Figure 4) .
As seen in Figure 2 , treatment with both doses of MCI-186 inhibited the formation of brain edema in a Sodium concentration in the embolized left hemisphere was reduced by 8.5% and that of potassium was increased by 5.3% compared with control in rats receiving 1.0 mg/kg MCI-186. These changes were slight and nonsignificant. MCI-186 at 3.0 mg/ kg significantly reduced the sodium concentration in the embolized left hemisphere (by 21.5%) and increased the potassium concentration (by 16.7%) compared with control ( Figures 3 and 4) . Thus, MCI-186 not only reduced water content but also normalized the sodium-potassium balance in a dosedependent manner. Dexamethasone at 1.0 mg/kg significantly attenuated brain edema formation by 1.5%, reducing the sodium concentration by 19% compared with control in the left hemispheres. Potassium concentration was enhanced slightly (by 11.9%). However, 3.0 mg/kg dexamethasone had no influence on water content (Table 1) .
Water content and electrolyte concentrations remained unchanged by PVA embolization 30 minutes after administration of 4.0 mg/kg indomethacin (Table 1) .
Discussion
It is well accepted that one of the most common features of cerebral ischemia is the development of brain edema. However, there is a paucity of effective drugs available for the therapy of brain edema. We have determined the activity of a free radical scavenger, MCI-186, upon PVA-induced edema in rat brain. The water-insoluble resin PVA was first used by Whisnant 7 in dogs. We followed the same procedure to produce a model of persistent ischemic brain edema having low mortality (3% of the 32 controls within 24 hours) in rats. When the concentrations and volumes of PVA injected into the left internal carotid artery are controlled carefully, an ischemic type of hemispheric brain edema develops easily and is highly reproducible in rats.
Although the ultimate cause of the brain edema following cerebral ischemia is not yet known, much attention has been paid to the role of free radicals and lipid peroxides as the injurious factors. During brain ischemia, levels of free fatty acids increase in the brain, 8 -9 and free arachidonic acid concentration decreases faster than that of other free fatty acids after ischemia. Through these alterations of free arachidonic acid concentration, some biologically active substances are derived by cyclooxygenase or lipoxygenase, 10 -12 and these active substances may be factors in the development of postischemic brain edema.
13
- 14 It has also been suggested that a marked generation of free radicals derived from the metabolism of arachidonic acid may also cause cytologic deterioration during prolonged cerebral ischemia 15 and that this may aggravate brain edema formation during reperfusion in transient cerebral ischemia. 16 Similarly, the introduction of arachidonic acid or a potent initiator of free radical reactions (such as FeCl 2 ) into the brain can induce edema in vivo 17 -19 ; the capacity for eicosanoid synthesis in brain microvessels is also known to be enhanced in conjunction with brain edema formation. 14 -20 Thus, these accumulated pieces of evidence suggest that the toxicity of free radicals and lipid peroxides for brain tissue may be one of the crucial factors in the development of ischemic brain edema. We examined the effect of MCI-186 on brain edema during prolonged cerebral ischemia, assuming that the development of edema and these toxicities might be related in the PVA-induced cerebral insult.
MCI-186 markedly attenuated both PVA-induced prolonged brain edema and neurologic deficits in a dose-dependent manner. This free radical scavenger inhibits both nonenzymatic lipid peroxidation 4 and lipoxygenase activity in vitro. 6 MCI-186 also inhibits damage to cultured endothelial cells caused by the lipid peroxidation product of arachidonic acid, 15-hydroxyeicosatetraenoic acid, 6 which causes a pronounced injury to dog basilar artery.
Low-dose dexamathasone (1.0 mg/kg i.v.) prevented PVA-induced brain edema; however, a higher dose (3.0 mg/kg i.v.) did not (Table 1) . Concerning the antiedema activity of dexamethasone in animal models, the situation is complex, especially as regards the doses used, 21 ' 22 and these variable effects are not yet fully elucidated.
The cyclooxygenase inhibitor indomethacin did not inhibit PVA-induced brain edema formation. This result supports a recent report showing that cyclooxygenase metabolites in the arachidonic acid cascade are unlikely to be involved in the prolonged formation of ischemic brain edema. 1 However, the dose of indomethacin effective against edema formation remains unclear. 23 Systemically administered indomethacin has been shown to cross the blood-brain barrier and inhibit the formation of cyclooxygenase metabolites in the brain. 24 - 26 Based on these findings, the dose of indomethacin we administered may have suppressed cyclooxygenase activity in brain tissue. It is conceivable, therefore, that the formation of brain edema induced by PVA embolization is unlikely to be mediated by cyclooxygenase metabolites of eicosanoids.
On the basis of these possibilities, we postulate from our data that the attenuation of PVA-induced edema by MCI-186 reflects free radical scavenging 4 and inhibition of lipoxygenase activity 6 in the arachidonic acid cascade. However, it may be necessary to elucidate further the additional possible mechanisms of the antiedema activity of MCI-186.
